Tatton Consulting supported Braintree-based oncology therapeutics company Spirea in its successful application to Investment Accelerator Pilot – Stream 2, awarded £104,123 by Innovate UK for the project Development of advanced therapies in cancer using a high loaded targeted delivery platform.
About the funded R&D project
Next-generation cancer drugs are potent enough that getting them to the tumour rather than the rest of the body determines whether they are usable. Spirea’s polymer platform carries a high drug load on a targeted delivery vehicle. This is the earliest of the company’s Innovate UK awards.
Award details
- Grant awarded: £104,123
- Competition: Investment Accelerator Pilot – Stream 2
- Competition year: 2017/18
- Project: Development of advanced therapies in cancer using a high loaded targeted delivery platform
- Sector: Oncology / drug delivery
- UKRI project record: Gateway to Research, project 133347
- Dataset: Innovate UK funded projects, published 10 August 2026
Tatton Consulting supported the competitive grant application. The award value, competition and project title are taken from UKRI’s published record for this project.
See all Innovate UK awards Tatton Consulting has supported on our grant successes page.
